drugset / Trial / NCT02321644

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

NCT02321644

Phase 1 Completed 26 enrolled Celgene Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a two-part, phase 1 study to evaluate the pharmacokinetics and pharmacodynamics of multiple doses of CC-90001 and the effects of food and formulation on the pharmacokinetics of single dose CC-90001 in healthy subjects. Part 1 involves the exposure of subjects to the minimum amount of UV-B light that causes minimally perceptible skin reddening. This will take place before dosing (baseline) and 3 times more while on increasing doses of CC-90001. Punch biopsies of the exposed areas will be taken and assessed for c-Jun terminal kinase activity. Part 2 involves evaluation of changes in pharmacokinetics of 2 formulations of CC-90001 when administered in the fasted state and after a high-fat meal.

Timeline

Start
2014-11
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CC-90001 Small molecule 60 mg Oral
Subject CC-90001 Small molecule 160 mg Oral
Subject CC-90001 Small molecule 200 mg Oral
Subject CC-90001 Small molecule 400 mg Oral

Indications

No indication recorded.